表紙
市場調査レポート

世界における経皮ドラッグデリバリー市場

Global Transdermal Drug Delivery Market 2014-2018

発行 TechNavio (Infiniti Research Ltd.) 商品コード 307321
出版日 ページ情報 英文 76 Pages
即納可能
価格
本日の銀行送金レート: 1USD=104.18円で換算しております。
Back to Top
世界における経皮ドラッグデリバリー市場 Global Transdermal Drug Delivery Market 2014-2018
出版日: 2014年06月30日 ページ情報: 英文 76 Pages
概要

経皮ドラッグデリバリーは、医薬品業界の中で大きな、また、順調に成長を遂げているセグメントです。世界の経皮ドラッグデリバリー市場は、2013年から2018年にかけて、9.92%のCAGRで拡大することが見込まれています。

当レポートでは、世界における経皮ドラッグデリバリー市場の現状と将来の見通し、市場の成長因子と課題、主要ベンダーのプロファイルなどを提供しています。

第1章 エグゼクティブサマリー

第2章 略語リスト

第3章 調査範囲

  • 市場概要
  • 主な製品

第4章 市場調査手法

  • 市場調査プロセス
  • 調査手法

第5章 イントロダクション

第6章 市場情勢

  • 市場概要
  • 市場規模と予測
  • ファイブフォース分析

第7章 経皮ドラッグデリバリー市場における競合の評価

第8章 経皮ドラッグデリバリーの最適化

第9章 アプリケーション別の市場区分

第10章 地理区分

第11章 購入基準

第12章 市場成長因子

第13章 成長因子とその影響

第14章 市場の課題

第15章 成長因子と課題の影響

第16章 市場動向

第17章 動向とその影響

第18章 ベンダー情勢

  • 競合シナリオ
    • 主なニュース
    • M&A
  • 市場シェア分析
  • その他の有力ベンダー

第19章 主要ベンダーの分析

  • ANI Pharmaceuticals Inc.
  • Antares Pharma Inc.
  • Bayer AG
  • Janssen Pharmaceuticals Inc.
  • Novartis AG

第20章 関連レポート

目次
Product Code: IRTNTR3714

About Transdermal Drug Delivery

Transdermal drug delivery is a large and growing vertical market of the Pharmaceutical industry. Transdermal drug delivery is defined as a system that utilizes skin as a site for continuous drug administration into the systemic circulation. Several methods of transdermal drug delivery include plasters, various ointments and, most commonly, patches. Transdermal drug administration has several advantages. First, the method of delivery is non-invasive, which is much less traumatic to the patient as compared to other forms of drug delivery. Also, it can be effective in assuring that a patient receives a full dosage of a drug and helps in increasing the compliance rate. However, there are difficulties associated with administering medication through the skin. The natural function of the skin is to act as a protective barrier, so it is often the case that drugs are not chemically suitable to penetrating the skin.

TechNavio's analysts forecast the Global Transdermal Drug Delivery market will grow at a CAGR of 9.92 percent over the period 2014-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Transdermal Drug Delivery market for the period 2013-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs administered transdermally and proprietary transdermal technologies available in the market. The Global Transdermal Drug Delivery market can be divided into five segments: Smoking Cessation, Pain Management, Hormone Therapy, Cardiovascular Indications, and Others.

TechNavio's report, the Global Transdermal Drug Delivery Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Transdermal Drug Delivery market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • EMEA
  • APAC

Key Vendors

  • ANI Pharmaceuticals Inc.
  • Antares Pharma Inc.
  • Bayer AG
  • Janssen Pharmaceuticals Inc.
  • Novartis AG

Other Prominent Vendors

  • 3M Pharmaceuticals Co.
  • Durect Corp.
  • Iontera Inc.
  • Isis Biopolymer Inc.
  • LTS Lohmann Therapie-Systeme AG
  • Mylan Laboratories Inc.
  • Nitto Denko Corp.
  • Pantec Biosolutions AG
  • Phosphagenics Ltd.
  • Tesa Labtec GmbH
  • Teva Pharmaceutical Industries Ltd.

Key Market Driver

  • Increase in Number of Transdermal Drug Delivery Products

For a full, detailed list, view our report

Key Market Challenge

  • Availability of Alternatives

For a full, detailed list, view our report

Key Market Trend

  • Increase in R&D Activities

For a full, detailed list, view our report

Key questions answered in this report:

  • What will the market size be in 2018 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast
  • 06.3. Five Forces Analysis

07. Competitive Assessment of Transdermal Drugs Delivery Market

08. Optimisation of Transdermal Drug Delivery

09. Market Segmentation by Application

10. Geographical Segmentation

11. Buying Criteria

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and their Impact

18. Vendor Landscape

  • 18.1. Competitive Scenario
    • 18.1.1. Key News
    • 18.1.2. Mergers and Acquisitions
  • 18.2. Market Share Analysis 2013
  • 18.3. Other Prominent Vendors

19. Key Vendor Analysis

  • 19.1. ANI Pharmaceuticals Inc.
    • 19.1.1. Key Facts
    • 19.1.2. Business Overview
    • 19.1.3. Business Strategy
    • 19.1.4. Business Segmentation
    • 19.1.5. Business Segmentation by Revenue 2013
    • 19.1.6. Business Segmentation by Revenue 2012 and 2013
    • 19.1.7. Key Developments
    • 19.1.8. SWOT Analysis
    • 19.1.9. Strengths
    • 19.1.10. Weaknesses
    • 19.1.11. Opportunities
    • 19.1.12. Threats
  • 19.2. Antares Pharma Inc.
    • 19.2.1. Key Facts
    • 19.2.2. Business Overview
    • 19.2.3. Business Segmentation
    • 19.2.4. Business Strategy
    • 19.2.5. Segmentation by Products
    • 19.2.6. Key Information
    • 19.2.7. SWOT Analysis
    • 19.2.8. Strengths
    • 19.2.9. Weaknesses
    • 19.2.10. Opportunities
    • 19.2.11. Threats
  • 19.3. Bayer AG
    • 19.3.1. Key Facts
    • 19.3.2. Business Overview
    • 19.3.3. Business Segmentation
    • 19.3.4. Business Strategy
    • 19.3.5. Sales Segmentation by Business
    • 19.3.6. Sales by Geographical Segmentation
    • 19.3.7. Key Information
    • 19.3.8. SWOT Analysis
    • 19.3.9. Strengths
    • 19.3.10. Weaknesses
    • 19.3.11. Opportunities
    • 19.3.12. Threats
  • 19.4. Janssen Pharmaceuticals Inc.
    • 19.4.1. Key Facts
    • 19.4.2. Business Overview
    • 19.4.3. Business Segmentation
    • 19.4.4. Business Strategy
    • 19.4.5. Key Developments
    • 19.4.6. SWOT Analysis
    • 19.4.7. Strengths
    • 19.4.8. Weaknesses
    • 19.4.9. Opportunities
    • 19.4.10. Threats
  • 19.5. Novartis AG
    • 19.5.1. Key Facts
    • 19.5.2. Business Overview
    • 19.5.3. Business Segmentation by Revenue 2013
    • 19.5.4. Business Segmentation by Revenue 2012 and 2013
    • 19.5.5. Sales by Geography
    • 19.5.6. Business Strategy
    • 19.5.7. Key Developments
    • 19.5.8. SWOT Analysis
    • 19.5.9. Strengths
    • 19.5.10. Weaknesses
    • 19.5.11. Opportunities
    • 19.5.12. Threats

20. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global Transdermal Drug Delivery Market 2013-2018 (US$ billion)
  • Exhibit 3: Global Transdermal Drug Delivery Market by Application
  • Exhibit 4: Global Transdermal Drug Delivery Market Segmentation 2013
  • Exhibit 5: Global Transdermal Drug Delivery Market by Geographical Segmentation
  • Exhibit 6: ANI Pharmaceuticals Inc.: Business Segmentation 2013
  • Exhibit 7: ANI Pharmaceuticals Inc.: Business Segmentation by Revenue 2013
  • Exhibit 8: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 9: Business Segmentation of Anatres Pharma, Inc. (2013)
  • Exhibit 10: Segmentation of Pipeline Products of Antares Pharma Inc. (2013)
  • Exhibit 11: Segmentation of Marketed Products of Antares Pharma Inc. (2013)
  • Exhibit 12: Business Segmentation of Bayer AG 2013
  • Exhibit 13: Sales Comparison of Bayer AG by Business Segment 2012 and 2013 (US$ million)
  • Exhibit 14: Sales Segmentation of Bayer AG by Geography 2013
  • Exhibit 15: Janssen Pharmaceuticals Inc.: Product Segmentation 2013
  • Exhibit 16: Novartis AG: Business Segmentation by Revenue 2013
  • Exhibit 17: Novartis AG: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 18: Novartis AG: Sales by Geography 2013
Back to Top